A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.

Trial Profile

A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Doxorubicin; Mitomycin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2013 New source identified and integrated (Mayo Clinic record: 10-004516).
    • 11 Jul 2012 Planned end date changed from 1 Sep 2012 to 1 Feb 2018 as reported by ClinicalTrials.gov.
    • 01 Oct 2010 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center, ctsu-E1208).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top